

# Nextleaf Solutions

07:00 29 Mar 2019

## Nextleaf gains as US patent granted for cannabinoid extraction from marijuana and hemp

Nextleaf Solutions Ltd (CSE:OILS) rose Thursday after announcing that the US Patent and Trade Office has granted a patent for its process of extraction, refinement and distillation of cannabinoids from marijuana and hemp.

The company said it is the first publicly traded entity to be issued an extraction patent. In addition, Nextleaf announced that it has been issued a standard patent from IP Australia, the government agency that administers intellectual property rights. The extraction process, according to Nextleaf, produces a tetrahydrocannabinol (THC) or cannabidiol (CBD) distillate that is tasteless, odorless and standardized for potency.

Shares of Nextleaf were up 7.7% to C\$0.35 in Thursday's Canadian trading.

**READ:** NextLeaf Solutions debuts on Canadian Securities Exchange  
Nextleaf said its patented technology allows for low-quality, dried cannabis biomass to be processed into a high-purity distilled oil, simplifying the manufacturing of differentiated cannabinoid formulations and delivery methods.

Applications for the extraction process included topicals, transdermal or sublingual delivery, vape technology, edible oils, beverages and water-soluble extracts, the company said.

"Nextleaf Solutions has succeeded in beating big pharma, big tobacco, big alcohol and every single billion-dollar cannabis company to the first issued patent for the extraction and purification of cannabinoids," Nextleaf CEO Paul Pedersen said in a statement. "We believe companies that can develop and protect valuable intellectual property will benefit substantially in the long term, especially in an industry as young as the cannabis industry."

The company made its debut on the Canadian Securities Exchange earlier this month.

-Updates share prices-

Contact Dennis Fitzgerald at [dennis@proactiveinvestors.com](mailto:dennis@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your

**Price:** C\$0.65

**Market Cap:** C\$57009400M

### 1 Year Share Price Graph



### Share Information

**Code:** OILS

**Listing:** CSE

**52 week High Low**  
C\$0.83 C\$0.30

**Sector:** Cannabis [T3]

**Website:** [www.nextleafsolutions.com](http://www.nextleafsolutions.com)

### Company Synopsis:

*Nextleaf Solutions Ltd. ("OILS") is the first publicly traded company to be issued a U. S. patent for industrial-scale extraction and purification of cannabinoids. OILS owns a portfolio of 3 issued and 24 pending patents pertaining to the production of high-purity cannabinoid distillate, the precursor used in the manufacturing of standardized THC and CBD based products.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.